Document resource
Introduction Gynaecological cancers increasingly affect women of reproductive age, necessitating fertility-sparing treatments that balance oncological safety with reproductive potential. However, the long-term impact of these treatments on survivorship—specifically regarding sexual function, quality of life (QoL) and reproductive outcomes—remains understudied. LIFE-Repro is a prospective multicentre cohort study designed to evaluate these impacts in young female cancer survivors.Methods and analysis Between 2023 and 2027, eleven tertiary referral hospitals in Korea will recruit 200 patients aged ≤45 years with gynaecological cancers who have undergone fertility-sparing treatment. Participants will undergo baseline assessments followed by prospective follow-ups every 6 months. At each visit, patient-reported outcomes assessing sexual function, QoL and health status will be collected using a mobile application developed by the research team. The primary endpoint is the incidence of post-treatment sexual dysfunction measured by the Female Sexual Function Index–Korean version. Secondary endpoints include longitudinal changes in QoL, cancer recurrence, survival, pregnancy rates, live birth rates and premature menopause.Ethics and dissemination The study protocol was approved by the Institutional Review Board of Korea University Guro Hospital (2024GR0484). Results will be disseminated through peer-reviewed journals and conference presentations.Trial registration number KCT0009578.